Skip to main content

Articles

Page 99 of 108

  1. Breast cancer arises from multiple genetic events that together contribute to the established, irreversible malignant phenotype. The development of inducible tissue-specific transgenics has allowed a careful d...

    Authors: James Hulit, Dolores Di Vizio and Richard G Pestell
    Citation: Breast Cancer Research 2001 3:209
  2. The involvement of β2-adrenergic receptor (ADRB2) and β3-adrenergic receptor (ADRB3) in both adipocyte lipolysis and thermogenic activity suggests that polymorphisms in the encoding genes might be linked with int...

    Authors: Xin-En Huang, Nobuyuki Hamajima, Toshiko Saito, Keitaro Matsuo, Mitsuhiro Mizutani, Hiroji Iwata, Takuji Iwase, Shigeto Miura, Tsutomu Mizuno, Shinkan Tokudome and Kazuo Tajima
    Citation: Breast Cancer Research 2001 3:264
  3. Chemotherapy is important in the systematic treatment of breast cancer. To enhance the response of tumours to chemotherapy, attention has been focused on agents to reverse multidrug resistance (MDR) and on the...

    Authors: Jie Li, Liang-Zhong Xu, Kai-Ling He, Wei-Jian Guo, Yun-Hong Zheng, Peng Xia and Ying Chen
    Citation: Breast Cancer Research 2001 3:253
  4. In embracing a multidisciplinary approach to the management of patients with sentinel node biopsy in breast cancer, the pathologist task is to screen sentinel nodes for possible metastasis. The consequences of...

    Authors: Rajendra S Rampaul, Ahmed Miremadi, Sarah E Pinder, Andrew Lee and Ian O Ellis
    Citation: Breast Cancer Research 2001 3:113
  5. Sentinel node biopsy is a minimally invasive technique to select patients with occult lymph node metastases who may benefit from further regional or systemic therapy. The sentinel node is the first lymph node ...

    Authors: Pieter J Tanis, Omgo E Nieweg, Renato A Valdés Olmos, Emiel J Th Rutgers and Bin BR Kroon
    Citation: Breast Cancer Research 2001 3:109
  6. Sentinel lymph node (SLN) biopsy requires validation by a backup axillary dissection in a defined series of cases before becoming standard practice, to establish individual and institutional success rates and ...

    Authors: Hiram S Cody III
    Citation: Breast Cancer Research 2001 3:104
  7. A large number of new potential chemoprevention agents are available that target molecular abnormalities found in estrogen receptor (ER)-negative and/or ER-positive precancerous breast tissue and have side eff...

    Authors: Carol J Fabian
    Citation: Breast Cancer Research 2001 3:99
  8. We examined lysosomal participation in the degradation of tumor cells from human breast biopsies, utilizing the histochemical activity and localization of acid phosphatase (AP). Enzyme activities in benign and...

    Authors: Reginald Halaby, Jafar Abdollahi and Minerva L Martinez
    Citation: Breast Cancer Research 2001 3:E002
  9. Breast cancers differ in response to treatment and may have a divergent clinical course despite having a similar histopathological appearance. New technology using DNA microarrays provides a systematic method ...

    Authors: James D Brenton, Samuel AJR Aparicio and Carlos Caldas
    Citation: Breast Cancer Research 2000 3:77

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 6.1
    5-year Journal Impact Factor: 7.1
    Source Normalized Impact per Paper (SNIP): 1.865
    SCImago Journal Rank (SJR): 2.578

    Speed 2023
    Submission to first editorial decision (median days): 14
    Submission to acceptance (median days): 129

    Usage 2023
    Downloads: 2,432,781
    Altmetric mentions: 1,561